Platelets are cells in the blood that constantly monitor for injury. When they identify an area of injury, they bind to the injury site through interaction of their surface receptors with injury site-specific proteins, like collagen and von Willebrand Factor. After adhesion to the injury site, platelets activate and change their shape and expression of other surface receptors, like GPIIb-IIIa. Upon activation, platelets become cross-linked through binding of blood protein fibrinogen. As the platelets pile up and plug the injury site, stabilization of the clot is achieved through the formation of a fibrin mesh. 

To address the shortcomings of donor platelet products, Haima is developing SynthoPlate, a platelet inspired, IV injectable drug that stops bleeding in patients with low platelet counts or platelet dysfunction. 

SynthoPlate is an IV-injectable hemostatic agent that mimics and amplifies platelet’s adhesion and aggregation functions. SynthoPlate is fully synthetic, available for large scale manufacture, easily portable, and requires no need for blood type matching.